Dupilumab, the world's first bio drug for atopic dermatitis, has been listed in China

On December 25, the marketing application of Sanofi dupilumab injection was undertaken by the drug examination center (acceptance No.: jxss1900067) Dupiluma is a human monoclonal antibody, which is used to treat the interleukin-4 (IL-4) receptor blocker of asthma and allergic dermatitis Jointly developed by Sanofi and Zaihuan In 2014, dupilumab was certified by FDA as a breakthrough treatment for atopic dermatitis On March 28, 2017, dupixent ® was approved by FDA to be the first biological agent for the treatment of moderate to severe atopic dermatitis According to the drug intelligence database, dupixent is currently carrying out a number of clinical trials in the world, among which, in China, dupilumab is being used in the three-stage clinical trials of adult patients with moderate and severe atopic dermatitis (clinical registration number: ctr20181386), and 160 people are planned to be enrolled The international multicenter phase 3 clinical treatment of COPD is also in progress (clinical registration number: ctr20191944) The planned number of participants: international multicenter trial: 924 in total, 82 in China At present, dupixent has been approved and listed by regulators in about 40 countries and regions including the United States, Japan and the European Union From the listing in 2017 to the sales growth in 2018 With the increasing of clinical indications and the expanding market, the drug will become the second best-selling anti-inflammatory drug in the world in the future after Abbott's Merlot Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.